A Phase 2, cross-indication resistant pathogen clinical trial of SPR-206 in patients with complicated urinary tract infection (cUTI), hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPR-206 (Primary)
Indications Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
Focus Therapeutic Use

Most Recent Events

27 Mar 2025 Status changed from planning to discontinued following a review and reprioritization of the Companys pipeline in Q1 2025
15 May 2024 According to a Spero Therapeutics media release, company plans to initiate a Phase 2 clinical trial contingent on availability of non-dilutive funding in March 2024.
28 Feb 2024 Planned number of patients changed to 60.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight